Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Drug Dissolution: Requirements and Profile Comparison01:14

Drug Dissolution: Requirements and Profile Comparison

The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Why is research fraud wrong?

International journal of general medicine·2013
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Brinzolamide-timolol suspension: acceptability and side effect profile.

Md Doherty1, Sg Fraser, Ps Phelan

  • 1Sunderland Eye Infirmary, Sunderland, Tyne and Wear, UK.

Clinical Ophthalmology (Auckland, N.Z.)
|April 19, 2011
PubMed
Summary

Brinzolamide-timolol suspension, a topical ocular antihypertensive, shows good tolerability and minimal impact on patient quality of life. Most patients prefer it over other eye drop treatments.

Keywords:
glaucomaintraocular pressurequality of lifeside effects

Related Experiment Videos

Last Updated: Jun 2, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Glaucoma Management

Background:

  • Topical ocular antihypertensive medications are crucial for managing glaucoma.
  • Brinzolamide-timolol suspension is a commonly prescribed treatment.
  • Understanding patient-reported side effects is essential for adherence and efficacy.

Purpose of the Study:

  • To assess the frequency, nature, and impact of side effects associated with brinzolamide-timolol suspension.
  • To evaluate patient quality of life and acceptability of the medication.
  • To compare patient experience with brinzolamide-timolol suspension to previously used topical treatments.

Main Methods:

  • A questionnaire-based study involving 76 glaucoma patients using brinzolamide-timolol suspension.
  • Patients rated effects on daily life, vision blurring, stinging, and irritation on a 0-10 scale.
  • Acceptability was assessed by comparing the suspension to prior topical medications.

Main Results:

  • 100% patient response rate (76 patients, aged 68-95).
  • Quality of life was minimally affected (scores 0-2).
  • Visual blurring was reported (scores 3-4), but stinging and irritation were infrequent (scores 0-1).
  • The majority preferred brinzolamide-timolol suspension over previous treatments.

Conclusions:

  • Brinzolamide-timolol suspension is well-tolerated and acceptable for glaucoma patients.
  • The medication has a minimal impact on patient quality of life.
  • Patient preference suggests favorable comparison with other topical ocular antihypertensives.